Anixa Biosciences Inc logo

Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. Anixa's proprietary Somatichrome™ technology platform allows for the targeting of any antigen to the cell surface for presentation via a novel endogenous immune receptor known as the i-CAR (Immune Cell-Associated Recognition). This vector reutilization approach is designed to enable a best-in-class antibody replacement strategy. Anixa has established a diverse pipeline of product candidates in inactivated virus, toxoid and tumor antigens that includes several Phase II cancer vaccine candidate assets. Anixa's lead cancer vaccine asset is VGX-3100, the first antigen-specific cancer vaccine candidate focused on Merkel cell carcinoma.

Latest events on Quartr

Previous Events for Anixa Biosciences Inc

Ticker

ANIX

Country

United States of America

About the company

https://www.anixa.com/about/overview

Investor Relations page

https://ir.anixa.com/

Dig deeper into the fundamentals using Quartr - Investor relations

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
Android play link
App store link
Quartr app screenshot